Terminated PHASE2 INTERVENTIONAL 2-arm NCT00537602

Miglustat / OGT 918 in the Treatment of Cystic Fibrosis

Single Center, Double-blind, Randomized, Placebo-controlled, 2-period/2-treatment Crossover Study Investigating the Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the ΔF508 Mutation

Sponsor: Actelion

Conditions Cystic Fibrosis

Interventions miglustat placebo

Updated 5 times since 2017 Last updated: Feb 11, 2010 Started: Nov 30, 2007 Primary completion: Feb 29, 2008 Completion: Mar 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Methodology applied did not meet all criteria required per guidelines

Other terminated trials from Actelion

See all terminations from Actelion

Other Cystic Fibrosis trials with similar outcome

Browse all Cystic Fibrosis trials

Listed as NCT00537602, this PHASE2 trial focuses on Cystic Fibrosis and remains terminated or withdrawn. Sponsored by Actelion, it has been updated 5 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Actelion

Data source: Actelion

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Barcelona, Spain